Homburger advised Novartis AG on its USD 12 bn acquisition of Avidity Biosciences, Inc.
On March 2, 2026, Novartis AG (SIX: NOVN / NYSE: NVS), acting through one of its wholly-owned indirect subsidiaries,
Homburger advised EQT on the sale of ca. 14.3% of Galderma’s share capital via an accelerated bookbuilding process exiting in full their investment
On March 10, 2026, a consortium led by EQT, consisting of Sunshine SwissCo GmbH, the Abu Dhabi Investment Authority (ADIA) and Auba Investment Pte. Ltd. (all acting as the Sellers), announced the launch of an accelerated
Homburger advised Roche Holding in the refinancing of its USD 7.5 bn revolving credit facility
On March 6, 2026, Roche Holding AG, Roche Holdings, Inc. and Roche Finanz AG entered into a Swiss law governed USD 7.5 bn revolving credit facility agreement arranged by and syndicated among twelve international banks, coordinated by Deutsche Bank.
Homburger advised Element Solutions on the acquisition of Micromax from Celanese
On February 2, 2026, Element Solutions Inc (NYSE: ESI), a global and diversified specialty chemicals technology company, announced that it has completed its previously announced acquisition of Micromax from Celanese Corporation (NYSE: CE) for approximately USD 500 m in cash.
Homburger advised ADC Therapeutics on the amendment of the financing agreement with HealthCare Royalty
On February 23, 2026, ADC Therapeutics SA (NYSE: ADCT) announced that it had amended its royalty purchase agreement with entities managed by HealthCare Royalty.
Homburger advised Raiffeisen Schweiz Genossenschaft on issuance of CHF 465 m State Treasury Notes by the State of North Rhine-Westphalia under its Debt Issuance Programme
On February 18, 2026, the State of North Rhine-Westphalia successfully completed its issuance of (i) CHF 100 m in aggregate principal amount of 0.3675 per cent.
Homburger advised Zurich Insurance Group Ltd on the placement of 7,090,909 newly issued shares through an accelerated bookbuilding process, raising gross proceeds of CHF 3.9 bn
On March 2, 2026, Zurich Insurance Group Ltd (SIX: ZURN) announced the launch of an accelerated bookbuilding offering, which led to the successful placement of 7,090,909 newly issued shares at an offer price of CHF 550 per offered share, raising aggregate gross proceeds of approximately CHF 3.9 bn. Zurich intends to use the net proceeds …
Homburger advised Zurich Insurance Company Ltd in connection with new debt facilities entered into in relation to Zurich Insurance Group Ltd’s offer for Beazley plc
On March 2, 2026, Zurich Insurance Group Ltd (SIX: ZURN) announced its recommended all-cash offer for the entire issued and to be issued share capital of Beazley plc (Beazley). The transaction combines two highly complementary businesses, accelerating Zurich’s strategy to create the global leader in Specialty insurance.
Homburger advised UBS Switzerland AG on the issuance of EUR 1.5 bn aggregate amount Fixed Rate Covered Bonds
On February 18, 2026, UBS Switzerland AG successfully completed its issuance of EUR 750 m 2.5595 per cent.
Homburger advises Solabia Développement S.A.S. on its acquisition of the Mibelle Biochemistry Business from Persán
On February 19, 2026, Solabia Group announced that it has entered into an agreement to acquire the Mibelle Biochemistry Business from Persán, a multinational European market leader in home and personal care. The Mibelle Biochemistry Business, part of the Mibelle Group, is a Swiss innovator specializing in the development and production of high‑performance active ingredients …